Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Feb;63(2):426-439.
doi: 10.1111/epi.17150. Epub 2021 Dec 27.

Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial

Elizabeth A Thiele  1 , E Martina Bebin  2 , Francis Filloux  3 , Patrick Kwan  4 , Rachael Loftus  5 , Farhad Sahebkar  6 , Steven Sparagana  7 , James Wheless  8
Affiliations
Clinical Trial

Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial

Elizabeth A Thiele et al. Epilepsia. 2022 Feb.

Abstract

Objective: To evaluate the long-term safety and efficacy of add-on cannabidiol (CBD) in patients with seizures associated with tuberous sclerosis complex (TSC) in the open-label extension (OLE) of the randomized, placebo-controlled phase 3 trial GWPCARE6 (NCT02544763). Results of an interim (February 2019 data cut) analysis are reported.

Methods: Patients who completed the randomized trial enrolled to receive CBD (Epidiolex® in the United States; Epidyolex® in the EU; 100 mg/mL oral solution). The initial target dose was 25 mg/kg/day, which, based on response and tolerability, could be decreased or increased up to 50 mg/kg/day. The primary end point was safety. Key secondary end points included percentage reduction in TSC-associated (countable focal and generalized) seizures, responder rates, and Subject/Caregiver Global Impression of Change (S/CGIC).

Results: Of 201 patients who completed the randomized phase, 199 (99%) entered the OLE. Mean age was 13 years (range, 1-57). At the time of analysis, 5% of patients had completed treatment, 20% had withdrawn, and 75% were ongoing. One-year retention rate was 79%. Median treatment time was 267 days (range, 18-910) at a 27 mg/kg/day mean modal dose. Most patients (92%) had an adverse event (AE). Most common AEs were diarrhea (42%), seizure (22%), and decreased appetite (20%). AEs led to permanent discontinuation in 6% of patients. There was one death that was deemed treatment unrelated by the investigator. Elevated liver transaminases occurred in 17 patients (9%) patients; 12 were taking valproate. Median percentage reductions in seizure frequency (12-week windows across 48 weeks) were 54%-68%. Seizure responder rates (≥50%, ≥75%, 100% reduction) were 53%-61%, 29%-45%, and 6%-11% across 12-week windows for 48 weeks. Improvement on the S/CGIC scale was reported by 87% of patients/caregivers at 26 weeks.

Significance: In patients with TSC, long-term add-on CBD treatment was well tolerated and sustainably reduced seizures through 48 weeks, with most patients/caregivers reporting global improvement.

Keywords: antiseizure medication; cannabidiol; epilepsy; focal seizures; treatment-resistant epilepsy; tuberous sclerosis complex.

PubMed Disclaimer

Conflict of interest statement

Elizabeth A. Thiele received support from GW Research Ltd as an investigator during the conduct of the trial; outside of the current work, she serves as a principal investigator on clinical trials for GW Research Ltd and Zogenix and serves as a consultant for Aquestive Therapeutics, Biocodex, West Therapeutics, Greenwich Biosciences, and Zogenix. E. Martina Bebin received support from GW Research Ltd as a site principal investigator during the conduct of the trial and serves as a consultant for Greenwich Biosciences and Biocodex. Francis Filloux and Patrick Kwan have nothing to disclose. Rachael Loftus is a full‐time employee of GW Research Ltd. Farhad Sahebkar is a full‐time employee of Greenwich Biosciences. Steven Sparagana has received personal compensation for serving as a consultant for Greenwich Biosciences and Nobelpharma. His institution has received research support from Greenwich Biosciences, Tuberous Sclerosis Complex Alliance, and Novartis. He has a noncompensated relationship as a professional advisory board member or committee member with Tuberous Sclerosis Complex Alliance. James Wheless has received personal compensation for serving as a consultant for Eisai, Supernus, Aquestive, GW Pharmaceuticals companies, and Neurelis. He has served on a speakers bureau for LivaNova, Eisai, Supernus, GW Pharmaceuticals companies, UCB, BioMarin, and Zogenix. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Figures

FIGURE 1
FIGURE 1
Patient disposition. aOne patient taking cannabidiol (CBD) 25 mg/kg/day in the randomized phase was withdrawn after completing the treatment because of vomiting and did not enter the open label extension (OLE); another patient taking CBD 50 mg/kg/day did not enter the OLE after completing treatment in the randomized phase because of logistical problems and on psychiatrist's recommendation. bWithdrawals are reported by the primary reason reported for each patient. cOne patient met the withdrawal criterion of elevation in ALT/AST levels. dOf patients who had other reasons, nine withdrew due to lack of efficacy, one withdrew because of difficulty maintaining compliance, and one switched to a commercial product. Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CBD, cannabidiol; OLE, open‐label extension
FIGURE 2
FIGURE 2
Reduction in (A) TSC‐associated seizure frequency and (B) total seizure frequency. (A) Data from the randomized, controlled phase of the trial are presented here for comparison. Abbreviations: CBD, cannabidiol; Q1, first quartile; Q3, third quartile; TSC, tuberous sclerosis complex; WD, number of patients who withdrew during a treatment window
FIGURE 3
FIGURE 3
Responder rates for (A) TSC‐associated seizures and (B) total seizures. Abbreviation: TSC, tuberous sclerosis complex
FIGURE 4
FIGURE 4
Global impression of change in patients' overall condition on the S/CGIC and PGIC scales at the 26‐week visit. Abbreviations: PGIC, Physician Global Impression of Change; S/CGIC, Subject/Caregiver Global Impression of Change
See this image and copyright information in PMC

References

    1. Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus Group . Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2012;2013(49):243–54. - PMC - PubMed
    1. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372:657–68. - PubMed
    1. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355:1345–56. - PubMed
    1. Wang S, Fallah A. Optimal management of seizures associated with tuberous sclerosis complex: current and emerging options. Neuropsychiatr Dis Treat. 2014;10:2021–30. - PMC - PubMed
    1. Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin‐Kowalik J, et al. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol. 2004;63:1236–42. - PubMed

Publication types

Associated data